| Item type |
itemtype_ver1(1) |
| 公開日 |
2022-02-28 |
| タイトル |
|
|
タイトル |
Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis |
|
言語 |
en |
| 著者 |
Nakamura, Masanao
Yamamura, Takeshi
Maeda, Keiko
Sawada, Tsunaki
Mizutani, Yasuyuki
Ishikawa, Eri
Ishikawa, Takuya
Kakushima, Naomi
Furukawa, Kazuhiro
Ohno, Eizaburo
Kawashima, Hiroki
Honda, Takashi
Ishigami, Masatoshi
Fujishiro, Mitsuhiro
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利 |
|
|
言語 |
en |
|
権利情報Resource |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
|
権利情報 |
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
ulcerative colitis |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
refractory |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
tofacitinib |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
case reports |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Ulcerative colitis (UC) is an incurable, chronic inflammatory disease of the large bowel whose etiology and pathogenesis have not yet been comprehensively explained. Tofacitinib is a small molecule Janus kinase inhibitor that was introduced for treating refractory UC. We aimed to examine the efficacy and safety of tofacitinib for the treatment of 18 patients with UC. Continuous treatment rates were 50, 38, and 33% at 8, 24, and 52 weeks, respectively. Overall, 83.3% of these patients showed tumor necrosis factor (TNF) antibody failure status. When the effective status was defined as a Lichtiger index (LI) that decreased by 3 points or more or was less than 4 points and remission status was defined as an LI less than 4 points, the effective and remission rates (%) at 2, 8, and 16 weeks were 55.5 (10/18) and 22.2 (4/18), 38.8 (7/18) and 33.3 (6/18), and 38.8 (7/18) and 38.8 (7/18), respectively. Background characteristics of 2-week responders and non-responders were compared. C-reactive protein level in responders was significantly lower than that in non-responders, and the hemoglobin level in responders was significantly higher than that in non-responders. This study provides preliminary results of the effectiveness of tofacitinib even for TNF antibody and tacrolimus failure patients. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Nagoya University Graduate School of Medicine, School of Medicine |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
departmental bulletin paper |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| ID登録 |
|
|
ID登録 |
10.18999/nagjms.84.1.169 |
|
ID登録タイプ |
JaLC |
| 関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/841.html |
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0027-7622 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2186-3326 |
| 書誌情報 |
en : Nagoya Journal of Medical Science
巻 84,
号 1,
p. 169-179,
発行日 2022-02
|
18_Nakamura.pdf (4.2 MB)
.png)
